The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.35
Bid: 13.20
Ask: 13.50
Change: 0.00 (0.00%)
Spread: 0.30 (2.273%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 13.35
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Premier Miton advances; Advance Energy retreats

Fri, 27th May 2022 10:43

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Premier Miton Group PLC, up 11% at 124.88 pence, 12-month range 109.00p-207.00p. For the six months that ended March 31, the London-based asset manager says revenue rose 10% to GBP48.5 million from GBP43.9 million year-on-year. Pretax profit jumps 60% to GBP9.9 million from GBP6.2 million. However, assets under management at the end of March stand at GBP12.85 billion, down 7.8% from GBP13.93 billion at October 1.

----------

Big Technologies PLC, up 7.0% at 283.00 pence, 12-month range 188.21p-385.00p. The remote people monitoring technology firm says revenue in the four months to the end of April rises 18% annually to GBP13.9 million. "These positive trends lead the board to remain confident in the group's ability to deliver results at least in line with current market expectations," the company says.

----------

AIM - LOSERS

----------

Poolbeg Pharma PLC, down 13% at 6.88p, 12-month range 4.13p-13.30p. The stock returns some gains on Friday, having jumped 32% on Thursday. The London-based pharmaceutical company on Thursday said it won patent grants from the US Patent & Trademark Office for its POLB 001 and POLB 002 molecules. The former is used to treat influenza, while the latter is an RNA-based immunotherapy for respiratory virus infections.

----------

Advance Energy PLC, down 19% at 0.15p, 12-month range 0.0017p-0.18p. The company says a production sharing contract will lapse, turning the energy firm into a cash shell, under AIM rules. Carnarvon Petroleum Timor has opts against entering the next period of the TL-SO-T 19-14 production sharing contract, which Advance calls the Buffalo licence. It is located in southeast Asian nation East Timor. It now has six months to make an acquisition that constitutes as a reverse takeover. Or it can become an investing company, which requires the raising of at least GBP6 million.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
20 Jul 2022 12:04

IN BRIEF: Poolbeg Pharma shares rise as first human trial begins

Poolbeg Pharma PLC - London-based pharmaceutical company - Receives approval to commence its Lipopolysaccharide human clinical trial for POLB 011, a drug that aims to treat severe influenza. The trial will formally start on Friday. It will assess POLB 011 in damping the immune response to lipopolysaccharide, which acts as a surrogate for the hyperinflammatory response associated with severe influenza. Initial results are expected in the final quarter of 2022. Poolbeg says at that point it intends to "rapidly" monetise by out-licensing and/or partnering with pharmaceutical and biotechnology companies for the drug's further development.

Read more
27 Jun 2022 10:47

Poolbeg Pharma AI model of respiratory syncytial virus starts analysis

(Alliance News) - Poolbeg Pharma PLC on Monday said its build and optimisation of an artificial intelligence model of respiratory syncytial virus data is complete.

Read more
26 May 2022 16:54

IN BRIEF: Poolbeg Pharma shares soar on US patent grants

Poolbeg Pharma PLC - London-based pharmaceutical company - Wins patent grants from the US Patent & Trademark Office for its POLB 001 and POLB 002 molecules. The former is used to treat influenza, while the latter is an RNA-based immunotherapy for respiratory virus infections. "The company is continuing working with its patent advisors to broaden and expand the POLB 001 and POLB 002 patent families," Poolbeg says.

Read more
26 May 2022 10:51

AIM WINNERS & LOSERS: Poolbeg wins patents; RA swings to loss

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
12 May 2022 15:35

TRADING UPDATES: Secure Trust lending up; Eurocell sales climb

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
27 Apr 2022 20:15

IN BRIEF: Poolbeg hails shareholder confidence as lock-up period ends

Poolbeg Pharma PLC - London-based pharmaceutical company - Confirms proposals have been accepted by distribution in specie shareholders seeking to sell a total of GBP366,000 of Poolbeg shares, representing only 3% of the distribution in specie shares. Says 97% of distribution in specie shareholders have decided to remain invested in Poolbeg following the end of the lock-up period.

Read more
14 Apr 2022 21:36

TRADING UPDATES: Polar Capital assets up; Brooks Macdonald funds fall

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
14 Apr 2022 14:53

Poolbeg granted European patent for antiviral nose spray

(Sharecast News) - Clinical-stage pharmaceutical company Poolbeg Pharma reported on the strengthening of its intellectual property (IP) for its 'POLB 002' asset on Thursday - a first-in-class, intranasally-administered RNA-based immunotherapy for respiratory virus infections.

Read more
13 Apr 2022 19:46

TRADING UPDATES: McKay backs Workspace offer; IOG fixes Blythe fault

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
11 Apr 2022 21:58

TRADING UPDATES: TruFin raises GBP10 million, Afentra preferred bidder

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
11 Apr 2022 10:57

AIM WINNERS & LOSERS: Mothercare misses payment; Argos licence renewed

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
31 Mar 2022 21:07

TRADING UPDATES: SSE's Transmission raises cash; Croda gets UK grant

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
30 Mar 2022 19:25

IN BRIEF: Poolbeg Pharma starts trading on OTCQB Venture Market

Poolbeg Pharma PLC - London-based pharmaceutical company - Shares start trading on the OTCQB Venture Market in the US.

Read more
28 Mar 2022 15:10

UK shareholder meetings calendar - next 7 days

Tuesday 29 March 
Impax Asset Management Group PLCAGM
Tekmar Group PLCAGM
Wednesday 30 March 
Brunner Investment Trust PLCAGM
Mediazest PLCAGM
Micro Focus International PLCAGM
Parsley Box Group PLCGM re equity raise
Power Metal Resources PLCGM re carried forward losses
Power Metal Resources PLCAGM
Thursday 31 March 
Pressure Technologies PLCAGM
Red Rock Resources PLCAGM
Aukett Swanke Group PLCAGM
Various Eateries PLCAGM
Toople PLCAGM
BiVictriX Therapeutics PLCAGM
CloudCoCo Group PLCAGM
Friday 1 April 
Gfinity PLCGM re fundraising
River & Mercantile Group PLCAGM
Monday 4 April 
Poolbeg Pharma PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.